Peptide Compounding Law for Pharmacists: 503A, 503B and the New HHS Policy

If you work in a pharmacy, you may already be asked about peptides. This guide covers the legal framework a pharmacist should have in mind. It is educational and not legal advice; confirm requirements with your State board of pharmacy and counsel.

The Section 503A Framework

Section 503A of the FD&C Act (21 U.S.C. 353a) describes the conditions a human drug product compounded by a licensed pharmacist in a State-licensed pharmacy or Federal facility, or by a licensed physician, must satisfy to be exempt from three requirements: FDA approval before marketing (section 505), labeling with adequate directions for use (section 502(f)(1)), and current good manufacturing practice (section 501(a)(2)(B)).²

One of the conditions concerns bulk drug substances. The compounder must use bulk substances that:²

1. comply with the standards of an applicable USP or NF monograph, if one exists, and the USP chapter on pharmacy compounding; or
2. if no monograph exists, are components of FDA-approved drugs; or
3. if no monograph exists and the substance is not a component of an approved drug, appear on a list developed by the Secretary through regulations under section 503A(c)(1).

The bulks list is codified at 21 CFR 216.23(a).⁷ HHS's own document notes that the Secretary convened and consulted the Pharmacy Compounding Advisory Committee (PCAC) as the statute requires to issue those regulations, and that FDA must also consult USP.² HHS's document highlights two further conditions: the bulk substance must be manufactured by an establishment registered under section 510 and accompanied by a valid certificate of analysis for each bulk substance, and the product must be compounded based on receipt of a valid patient-specific prescription.²

503A and 503B

Outsourcing facilities operate under section 503B, and FDA's bulk-substance interim policies refer to separate 503A and 503B bulks lists and categories.³ The October 30 HHS policy is titled and written for 503A compounding, so this guide treats 503B facilities as outside it.¹

Why Peptides Fall Into the Gap

BPC-157 has no USP or NF monograph and is not a component of an FDA-approved drug, so the only available route is the bulks list. FDA's process for substances nominated for the lists sorts them under interim policies, and its published safety assessments for several peptides cite possible immune reactions (for some, from aggregation) and peptide-related impurities, difficulty characterizing the active ingredient, and little or no human safety data. FDA's page lists BPC-157, epitalon, KPV, MOTS-c, semax and TB-500 among nominated substances since withdrawn by their nominators; that page's content was current as of April 22, 2026, and HHS's Appendix B says BPC-157 was in category 2 from September 2023 until April 22, 2026, with neither the placement nor the removal changing its status under section 503A.³

On July 23 and 24, 2026, the PCAC reviewed seven peptides and recommended six: BPC-157, KPV, TB-500, MOTS-c, semax and epitalon. Press reports put the BPC-157 vote at 8 in favor, 6 against, 1 abstention, against the view of FDA's own reviewers; FDA has not published tallies on its meeting page.⁴⁵ A committee recommendation is advice. Listing requires notice-and-comment rulemaking,⁶ and as of November 1, 2026 I found no FDA proposed rule on these peptides in the Federal Register. I cover the vote in BPC-157 and the FDA: What the July 2026 Hearing Actually Means.

The HHS Draft Enforcement Discretion Policy

On October 30, 2026, HHS announced the availability of a draft “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances” (91 FR 68526; Docket HHS-OASH-2026-0496).¹ It applies while the 503A bulks list is developed through rulemaking. HHS states that it “does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician” compounding with a peptide in Appendix A, and that FDA's future rulemakings “may propose adding some or all of these peptides.”¹

Appendix A lists six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500.² The short bold labels below are mine, not HHS's. The policy applies to a peptide that is not a component of an approved drug, not the subject of a USP or NF monograph and not on the codified bulks list, and only when all ten conditions are present:²

1. Appendix A. The peptide is on the list.
2. Identity and route. It has the identity and route limits in Appendix B. Identity includes but is not limited to amino acid sequence, chemical structure, molecular weight and molecular formula. For BPC-157, Appendix B limits coverage to BPC-157 acetate in subcutaneous, intramuscular, oral and topical dosage forms; other forms and routes, such as intravenous, are not covered.
3. Characterization. It comes from a facility registered under section 510 and is identified in a valid certificate of analysis with test results consistent with FDA guidance-based criteria, showing identity, purity, potency and the absence of harmful contaminants such as endotoxins, heavy metals, microbial contamination and impurities.
4. Original manufacturer. The original manufacturer, not a later packer, repacker, labeler or distributor, is registered, is in compliance with CGMP and other FD&C requirements, and its physical location is listed on the certificate of analysis. If a registered repacker or reseller is used, it has performed and documented vendor validation of the manufacturer and of the manufacturer’s certificate of analysis.
5. Reporting. The compounder reports serious adverse events (whether or not considered drug related) and product quality issues to FDA's MedWatch program and to the States involved, and also reports the products compounded: active ingredient and strength, original manufacturer with its facility identifier, and dosage form and route. The labeling tells the patient how to report.
6. Labeling. The label says: “This is a compounded drug product. Not for resale.”
7. Single API. The product contains only one Appendix A active ingredient.
8. Route. For oral products, the compounder keeps documentation that the formulation achieves adequate oral bioavailability.
9. Device. The only device co-packaged is an FDA 510(k)-cleared syringe.
10. Everything else. The product is compounded in compliance with all other FD&C Act requirements, including not being prepared under insanitary conditions and the patient-specific prescription requirement.

What this means at the counter

These are my readings of the draft's text, not legal advice. A product combining two peptides, such as a BPC-157 and TB-500 blend, would not satisfy the single-API condition as written. A vial from a “research use only” supplier, with no registered original manufacturer and no certificate of analysis tying the lot to a registered facility, would not satisfy conditions 3 and 4. A prescription is still required for each patient. And the policy speaks to federal enforcement only; your State board of pharmacy is a separate authority, so check your jurisdiction.

What it does not do

• It is a draft. The notice says it creates no rights and is not binding on HHS or the public.¹
• It does not add any peptide to the bulks list; that still requires rulemaking.¹
• HHS may revisit it, for example if a safety signal or product quality issue arises.¹
• The notice set a comment deadline of two weeks after publication, which works out to November 13, 2026, on Regulations.gov, and the notice points readers to HHS's website for the most current version.¹

For Pharmacy Students and Exam Candidates

Compounding is tested in the UMPJE's Domain 1, Pharmacy and Pharmacist Practice, which carries 30% of scored questions; see my UMPJE content outline guide. In my judgment, the durable material is the statutory framework above: the three bulk-substance routes, the patient-specific prescription requirement, the section 510 registration and certificate of analysis conditions, and the exemptions a compliant 503A product earns. A draft enforcement policy can change; the statute it sits on is what to learn. Test yourself with the free UMPJE practice questions, or read the full UMPJE prep hub.

For the clinical and evidence side of the most-searched peptide, see BPC-157: Benefits, Risks, Side Effects and the Truth Behind the Hype and the book BPC-157 Decoded.

Frequently Asked Questions